A $17.8 Billion Strategic Surge: AbbVie's Aggressive Expansion in the Neurological Field with $8.7 Billion Cerevel Acquisition and $10.1 Billion ImmunoGen Deal

On the evening of December 6th, AbbVie's official website announced plans to acquire Cerevel Therapeutics, a neuroscience biotechnology company, for a staggering $8.7 billion, further strengthening its presence in the neurological domain.

According to the terms of the agreement, AbbVie will pay $45 per share in cash for Cerevel. Following the announcement, Cerevel's stock price rose nearly 14% in after-hours trading, reaching approximately $42.09 per share. The market capitalization of Cerevel stood at $6.65 billion on the day the news broke.

What does AbbVie gain from its $8.7 billion investment in Cerevel?

Established in 2018 through a collaboration between Pfizer and Bain Capital, Cerevel aims to develop treatments for Parkinson's disease and schizophrenia, but has yet to bring any drugs to market.

Cerevel's pipeline includes the Phase II clinical-stage schizophrenia treatment, Emraclidine, which shares a similar mechanism of action with Karuna Therapeutics' drug, KarXT. Additionally, the company is advancing several other projects, including the Phase III-stage Parkinson's disease candidate, Tavapadon, the mid-stage focal epilepsy and panic disorder drug, Darigabat, and the Phase IIa-stage treatment for apathy associated with dementia, CVL-871.

The acquisition is expected to be completed by mid-2024, at which point AbbVie will gain access to mid-to-late-stage drugs for schizophrenia, epilepsy, Parkinson's disease, and dementia, expanding its neurology pipeline.

Earlier this year, Cerevel underwent changes in its top leadership, with Ron Renaud taking over as CEO from Tony Coles. Additionally, President Abraham Ceesay announced his departure and assumed the role of CEO at another neuroscience startup, Rapport Therapeutics.

Furthermore, this acquisition comes just two months after Cerevel announced a $498 million financing project in its third-quarter financial report. The funds from this acquisition will support the biotechnology company's operations until 2026.

Despite the executive changes, absence of commercialized products, and ongoing financing, AbbVie has boldly extended an olive branch to Cerevel, and an expensive one at that. This demonstrates AbbVie's confidence in Cerevel and its unwavering belief in the future of the neurology field.

The news of this acquisition has garnered significant attention in the pharmaceutical industry. However, AbbVie's interest in central nervous system biotechnology is not unfounded. During an analyst conference call on December 1st to discuss the ImmunoGen deal, AbbVie CEO Rick Gonzalez revealed the company's interest in CNS biotechnology.

Is AbbVie on a buying spree?

Just six days prior, AbbVie announced its $10.1 billion acquisition of ImmunoGen, acquiring their "first-in-class" antibody-drug conjugate (ADC), Elahere (mirvetuximab soravtansine), for the treatment of platinum-resistant ovarian cancer.

According to the agreement, AbbVie will acquire all outstanding shares of ImmunoGen at a price of $31.26 per share, totaling a staggering $10.1 billion. The acquisition has been approved by the boards of AbbVie and ImmunoGen, with completion expected by mid-2024.

This acquisition will grant AbbVie access to ImmunoGen's FDA-accelerated approval drug, Elahere (mirvetuximab soravtansine-gynx), as well as ImmunoGen's subsequent ADC pipeline. ImmunoGen is currently developing multiple ADCs for the treatment of solid tumors, acute myeloid leukemia, and plasmacytoid dendritic cell tumor, among others.

Elahere is an FRαADC composed of an antibody targeting the folate receptor, a cleavable linker, and the potent microtubule inhibitor DM4. It is the world's first drug targeting this specific receptor and is used as a monotherapy for the treatment of platinum-resistant ovarian cancer (PROC) with high FRα expression.

Elahere received FDA accelerated approval in November 2022, becoming a significant revenue generator for ImmunoGen. In the third quarter of 2023, ImmunoGen's total revenue exceeded $113 million, with Elahere contributing $105 million in sales compared to just $15 million in the same period the previous year, highlighting its remarkable market performance.

It's worth mentioning that in October 2020, Hangzhou Huadong Medicine, a wholly-owned subsidiary of China's Huadong Medicine, signed a strategic cooperation agreement with ImmunoGen. Huadong Medicine obtained exclusive clinical development and commercialization rights for Elahere in mainland China, Hong Kong, Macau, andTaiwan. It is unclear how AbbVie's acquisition of ImmunoGen will impact this existing agreement.

AbbVie's strategic move towards expanding its presence in the neurological field through the Cerevel and ImmunoGen acquisitions signals the company's commitment to diversifying its portfolio and tapping into promising therapeutic areas. Neurological disorders, such as Parkinson's disease, schizophrenia, and various forms of cancer, represent significant unmet medical needs, and AbbVie aims to leverage its resources and expertise to develop innovative treatments in these areas.

The completion of these acquisitions will provide AbbVie with a robust pipeline of potential therapies, bolstering its position as a leading pharmaceutical company. The success of these ventures will depend on the further development and regulatory approvals of the acquired assets. Nonetheless, AbbVie's aggressive expansion in the neurological field showcases its determination to make a meaningful impact on patients' lives and solidify its position as a key player in the pharmaceutical industry.